5%) 253 (75.7%)    IIIc 77 (22.9%) 81 (24.3%)    IV 2 (0.6%) Idasanutlin clinical trial 0 (0%) PFS 12 months 12 months OS 29 months 30 months Recurrent disease Despite the activity of first-line chemotherapy, which gives response rates up to 80% in first line treatment, the majority of patients die of their recurrent disease [2]. Therefore, a large proportion of patients are candidates for second-line treatment. Platinum sensitivity, which is defined by a response to first-line platinum-based therapy, has been found to predict the response to subsequent retreatment with a platinum-containing regimen frequently used for salvage therapy. In general, patients who progress

or have stable disease during first-line treatment or who relapse within 1 month are considered to be ‘platinum-refractory’. Patients who respond to primary treatment and relapse within 6 months are considered

‘platinum-resistant’, selleckchem and patients who relapse more than 6 months after completion of initial therapy are characterized as ‘platinum-sensitive’ [11]. It is known that longer platinum free interval (PFI) increases the chances for a benefit by platinum re-challenge. This has been reported especially for PFI longer than 12 months. Patients who are relapsing 6-12 months following the end of their initial regimen may benefit less and are, usually classified as so-called ‘partially sensitive’ [12] (Table 4). Table 4 Association of platinum sensitivity and PFI Platinum sensitivity resistant Dichloromethane dehalogenase sensitive   refractory resistant partially sensitive sensitive PFI during/immediately after chemotherapy < 6 months 6-12 months > 12 months Several randomized

trials have been performed in platinum-sensitive patients. The ICON-4/OVAR 2.2 study compared the PX-478 order combination chemotherapy (platinum plus paclitaxel) to single chemotherapy (platinum alone) in 802 patients with ‘platinum-sensitive’ relapsed ovarian cancer. Results demonstrated that both survival and progression free survival were significantly longer in combination therapy compared to platinum alone [13]. The optimal treatment of patients with partially platinum-sensitive recurrent ovarian cancer is not clearly defined. Trabectedin, a marine-derived antineoplastic agent initially isolated from the tunicate Ecteinascidia turbinate, has recently been introduced to this setting of patients. This agent is currently produced synthetically and its mechanism of anti-cancer action is based on DNA minor-groove binding [14]. Patients with platinum refractory and resistant are good candidates for novel investigational approaches and studies of drug resistance. Single-agent therapy is considered the standard treatment in these patients. Low response rates are recorded in these patients with the use of topotecan, docetaxel, oral stoposide, pegylated liposomal doxorubicin (PLD), gemcitabine, ifosfamide and hexamethylmelamine.